Finnish medtech company Nukute successfully closes its series A funding round and goes after COVID-19 – receives a strategic three million euro investment from the Pharmacy Pension Fund (Finland)

Medtech company Nukute raised funding of €4.1 million on its series A round, €4.9 million with public funding included. The single largest investment came from the Pharmacy Pension Fund (Finland), that believed in Nukute’s business with an investment of €3.0 million.

The company is moving forward with clinical trials and the obtaining of the CE marking for the added functionality to the Nukute Collare system. This addition will facilitate the remote monitoring of acute respiratory distress syndrome (ARDS) in COVID-19 patients. The funding will also be used for the entry to the European market and next generation product development.

For more information, please contact Nukute's chief marketing officer, Mr. Janne Regelin - janne.regelin@nukute.com, +358503768277